1. Home
  2. GRFS vs FOLD Comparison

GRFS vs FOLD Comparison

Compare GRFS & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Grifols S.A.

GRFS

Grifols S.A.

HOLD

Current Price

$8.27

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Logo Amicus Therapeutics Inc.

FOLD

Amicus Therapeutics Inc.

HOLD

Current Price

$14.49

Market Cap

4.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRFS
FOLD
Founded
1940
2002
Country
Spain
United States
Employees
25247
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.5B
4.5B
IPO Year
N/A
2006

Fundamental Metrics

Financial Performance
Metric
GRFS
FOLD
Price
$8.27
$14.49
Analyst Decision
Hold
Buy
Analyst Count
2
9
Target Price
$10.15
$27.25
AVG Volume (30 Days)
573.0K
2.4M
Earning Date
07-28-2022
05-06-2026
Dividend Yield
1.80%
N/A
EPS Growth
N/A
50.00
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$4.49
$20.50
Revenue Next Year
$6.42
$18.59
P/E Ratio
$18.67
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.08
$5.66
52 Week High
$11.14
$14.50

Technical Indicators

Market Signals
Indicator
GRFS
FOLD
Relative Strength Index (RSI) 50.07 74.18
Support Level $7.64 $14.21
Resistance Level $8.88 N/A
Average True Range (ATR) 0.18 0.02
MACD -0.02 -0.00
Stochastic Oscillator 38.54 100.00

Price Performance

Historical Comparison
GRFS
FOLD

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

About FOLD Amicus Therapeutics Inc.

Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.

Share on Social Networks: